December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 Next >
News headline image
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports H1 2025 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Up To $15.0 Million Public Offering
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
US Patent Office Granted Can-Fite Namodenoson Patent for Use as anti-Obesity Drug
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s anti-Cancer Drug Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.